Koizumi M, Maeda H, Yoshimura K, Yamauchi T, Kawai T, Ogata E
Department of Nuclear Medicine, Cancer Institute Hospital, Toshima-ku, Tokyo, Japan.
Br J Cancer. 1997;75(11):1601-4. doi: 10.1038/bjc.1997.273.
To clarify the meaning and clinical value of bone formation markers in bone metastasis from prostate cancer, we investigated the bone formation markers carboxy-terminal propeptide of type I procollagen (PICP), bone-specific alkaline phosphatase (BA1-p) and osteocalcin, so-called bone gla protein (BGP) in 43 prostate cancer patients with and 46 patients without overt bone metastasis. Patients with bone metastasis were evaluated repeatedly by bone scan at intervals of 3-6 months. The expression patterns of bone formation markers in patients with progression of bone metastasis became dissociated; BA1-p and PICP were elevated in patients with progression of bone metastasis but BGP was not. Instead, BGP showed slight elevation in patients with improvement and complete remission of bone metastasis. PICP, BA1-p and BGP are all bone formation markers, but each marker appears in a different phase of bone formation: PICP appears in proliferation phase, BA1-p appears in matrix maturation phase and BGP appears in late bone formation phase. Our findings that BGP was not elevated in progression of bone metastasis and that it increased slightly with improvement and complete remission of bone metastasis may imply that the bone formation that occurs in blastic bone metastasis is different from normal bone formation.
为阐明骨形成标志物在前列腺癌骨转移中的意义及临床价值,我们对43例有明显骨转移的前列腺癌患者和46例无明显骨转移的患者,研究了骨形成标志物I型前胶原羧基末端前肽(PICP)、骨特异性碱性磷酸酶(BA1-p)和骨钙素(即骨γ-羧基谷氨酸蛋白,BGP)。骨转移患者每隔3至6个月通过骨扫描进行重复评估。骨转移进展患者的骨形成标志物表达模式出现分离;骨转移进展患者的BA1-p和PICP升高,但BGP未升高。相反,骨转移改善和完全缓解患者的BGP略有升高。PICP、BA1-p和BGP均为骨形成标志物,但每种标志物出现在骨形成的不同阶段:PICP出现在增殖期,BA1-p出现在基质成熟期,BGP出现在骨形成后期。我们的研究结果表明,骨转移进展时BGP未升高,而在骨转移改善和完全缓解时略有升高,这可能意味着成骨性骨转移中发生的骨形成与正常骨形成不同。